Use of GBCA in MRIs for High-Risk Patients

Affiliations

¹ Ingrid Böhm is a Physician in the Department of Diagnostics, Interventional and Pediatric Radiology at the University Hospital of Bern, Inselspital, University of Bern in Bern, Switzerland.

Comment

Ingrid Böhm. Fed Pract. 2019 Apr.

. 2019 Apr;36(4):153-154.

¹ Ingrid Böhm is a Physician in the Department of Diagnostics, Interventional and Pediatric Radiology at the University Hospital of Bern, Inselspital, University of Bern in Bern, Switzerland.

No abstract available

Conflict of interest statement

Disclosures: The author reports no conflict of interest with regard to this article.

Initiative to Minimize Pharmaceutical Risk in Older Veterans (IMPROVE) Polypharmacy Clinic.
Gardner AL, Thomas JM, Mecca MC, Hyson A, Niehoff KM, Jeffery S, Sellinger J, Brienza R. Gardner AL, et al. Fed Pract. 2018 Nov;35(11):40-47. Fed Pract. 2018. PMID: 30766331 Free PMC article.

1. Chuang K, Kaneshiro C, Betancourt J. Nephrogenic systemic fibrosis in a patient with multiple inflammatory disorders. Fed Pract. 2018;35(6):40–43. - PMC - PubMed
1. Larson KN, Gagnon AL, Darling MD, Patterson JW, Cropley TG. Nephrogenic systemic fibrosis manifesting a decade after exposure to gadolinium. JAMA Dermatol. 2015;151(10):1117–1120. - PubMed
1. US Food and Drug Administration. A Public Health Advisory. Gadolinium-containing contrast agents for magnetic resonance imaging (MRI) [Accessed March 15, 2019]. http://wayback.archive-it.org/7993/20170112033022/ http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa.... Published June 8, 2006.
1. Kanal E, Barkovich AJ, Bell C, et al. ACR Blue Ribbon Panel on MR Safety. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007;188(6):1447–1474. - PubMed
1. European Medicines Agency. Public statement: Vasovist and nephrogenic systemic fibrosis (NSF) [Accessed March 15, 2019]. https://www.ema.europa.eu/en/news/public-statement-vasovist-nephrogenic-.... Published February 7, 2007.